Johann Chan
Amgen
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Johann Chan.
Journal of the American Chemical Society | 2010
Jinkun Huang; Johann Chan; Ying Chen; Christopher J. Borths; Kyle D. Baucom; Robert D. Larsen; Margaret M. Faul
Heteroarenes are important structural moieties in many chemical industry fields. A highly efficient Pd/Cu-catalyzed C-H arylation method for a range of heterocycles has been discovered. It was found that the key to the success of this transformation is a combination of a palladium catalyst and a well-defined copper cocatalyst. The efficiency and low loadings of catalyst (0.25 mol %) and cocatalyst (1 mol %) together with the mild reaction conditions demonstrate this method to be practically useful and mechanistically interesting.
Bioorganic & Medicinal Chemistry Letters | 2012
Xiaoqi Chen; Jeff Mihalic; Jeff Deignan; Darin Gustin; Jason Duquette; Xiaohui Du; Johann Chan; Zice Fu; Michael Johnson; An-Rong Li; Kirk Henne; Timothy J. Sullivan; Bryan Lemon; Ji Ma; Shichang Miao; George Tonn; Tassie L. Collins; Julio C. Medina
The optimization of a series of 8-aza-quinazolinone analogs for antagonist activity against the CXCR3 receptor is reported. Compounds were optimized to avoid the formation of active metabolites and time-dependent-inhibitors of CYP3A4. In addition, antagonists showed potent against CXCR3 activity in whole blood and optimized to avoid activity in the chromosomal aberration assay. Compound 25 was identified as having the optimal balance of CXCR3 activity and pharmacokinetic properties across multiple pre-clinical species, which are reported herein.
Journal of Organic Chemistry | 2011
Johann Chan; Brenda J. Burke; Kyle D. Baucom; Karl B. Hansen; Matthew M. Bio; Evan DiVirgilio; Margaret M. Faul; Jerry Murry
Two new, reliable syntheses of a pyrido[2,3-d]-pyrimidine inhibitor of the CXCR3 receptor are described. A nine-step synthesis of the CXCR3 inhibitor (1) from 2-aminonicotinic acid was demonstrated on a multikilogram scale and incorporates a classic resolution to deliver the enantioenriched active pharmaceutical ingredient (API). A second synthesis of the CXCR3 inhibitor starts from (+)-(D)-Boc alanine and 2-chloronicotinic acid and utilizes a Goldberg coupling. This second synthesis, performed on a gram scale, intersects the former route at a common intermediate thereby completing a formal synthesis of the enantioenriched API in higher overall yield without the need for a resolution.
Organic Letters | 2006
Anil Guram; Anthony O. King; John G. Allen; Xianghong Wang; Laurie B. Schenkel; Johann Chan; Emilio E. Bunel; Margaret M. Faul; Robert D. Larsen; Michael J. Martinelli; Paul J. Reider
Tetrahedron Letters | 2009
Robert R. Milburn; Ken McRae; Johann Chan; Jason Tedrow; Robert D. Larsen; Margaret M. Faul
Synlett | 2011
Jinkun Huang; Ying Chen; Johann Chan; Mike Ronk; Robert D. Larsen; Margaret M. Faul
Tetrahedron Letters | 2012
Ying Chen; Jinkun Huang; Tsang-Lin Hwang; T.J. Li; Sheng Cui; Johann Chan; Matthew M. Bio
Tetrahedron Letters | 2006
Johann Chan; Margaret M. Faul
Synthesis | 2007
Johann Chan; Darin Gustin; Evan DiVirgilio; Anil Guram; Margaret M. Faul
Tetrahedron Letters | 2007
Michal M. Achmatowicz; Johann Chan; Philip Wheeler; Longbin Liu; Margaret M. Faul